The U.S. Food and Drug Administration issued an emergency use authorization Tuesday that allows health care providers to change how the Jynneos monkeypox vaccine is administered, stretching out the supply amid high demand.The vaccine can now be given to high-risk adults intradermally, meaning between the layers of the skin, rather than subcutaneously, or under the skin, as it has been given up till now. This will allow providers to get five doses out of a standard one-dose vial.The new EUA also allows subcutaneous vaccination in people under 18 who are at high risk of infection."In recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand," FDA Commissioner Dr. Robert M. Califf said in a statement. "The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals. By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so."The move comes less than a week after the Biden administration declared monkeypox a public health emergency, which gives the FDA and other government health agencies more flexibility to fight the spread of the virus.Earlier Tuesday, U.S. Department of Health and Human Services Secretary Xavier Becerra issued a determination to pave the way for the FDA's move."Last week, I declared monkeypox to be a public health emergency to unlock additional tools that will help us contain and end this outbreak and to signal to the American people that we are taking our response to the next level," Becerra said in a statement. "Today's action will allow FDA to exercise additional authorities that may increase availability of vaccines to prevent monkeypox while continuing to ensure the vaccine meets high standards for safety, effectiveness and manufacturing quality."As of Monday, the U.S. government has shipped 617,693 doses of Jynneos to states and jurisdictions. The U.S. Centers for Disease Control and Prevention has estimated that at least 1.5 million people in the U.S. are eligible for monkeypox vaccination.As of Monday evening, the CDC reports 8,934 probable or confirmed monkeypox cases in 49 states, Puerto Rico and the District of Columbia.With an intradermal vaccination, "basically, you're staying in the skin; you're not going through the skin," said Dr. Daniel Griffin, an infectious disease specialist at Columbia University.Using a smaller dose with intradermal injection has been done with vaccines for flu and rabies, epidemiologist Dr. Jay Varma told CNN in an email."The skin has special cells that are very good at helping a vaccine stimulate the body's immune system," he wrote.These cells, called dendritic cells, are better able to produce an immune response, Griffin said."They live in the skin, and they're better at teaching the immune system what they need to respond to," he said."If you're able to give the monkeypox vaccine intradermally, you can give a smaller dose. ... They just would need to have some sort of demonstration that you get the same immune response," he said.
The U.S. Food and Drug Administration issued an emergency use authorization Tuesday that allows health care providers to change how the Jynneos monkeypox vaccine is administered, stretching out the supply amid high demand.
The vaccine can now be given to high-risk adults intradermally, meaning between the layers of the skin, rather than subcutaneously, or under the skin, as it has been given up till now. This will allow providers to get five doses out of a standard one-dose vial.
The new EUA also allows subcutaneous vaccination in people under 18 who are at high risk of infection.
"In recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand," FDA Commissioner Dr. Robert M. Califf said in a . "The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals. By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so."
The move comes less than a week after the Biden administration declared monkeypox a public health emergency, which gives the FDA and other government health agencies more flexibility to fight the spread of the virus.
Earlier Tuesday, U.S. Department of Health and Human Services Secretary Xavier Becerra issued a determination to pave the way for the FDA's move.
Mario Tama
A pharmacist prepares a dose of the Jynneos monkeypox vaccine at a pop-up vaccination clinic opened today by the Los Angeles County Department of Public Health at the West Hollywood Library on August 3, 2022 in West Hollywood, California.
"Last week, I declared monkeypox to be a public health emergency to unlock additional tools that will help us contain and end this outbreak and to signal to the American people that we are taking our response to the next level," Becerra said in a . "Today's action will allow FDA to exercise additional authorities that may increase availability of vaccines to prevent monkeypox while continuing to ensure the vaccine meets high standards for safety, effectiveness and manufacturing quality."
As of Monday, the U.S. government has shipped 617,693 doses of Jynneos to states and jurisdictions. The U.S. Centers for Disease Control and Prevention has estimated that at least 1.5 million people in the U.S. are eligible for monkeypox vaccination.
As of Monday evening, the CDC 8,934 probable or confirmed monkeypox cases in 49 states, Puerto Rico and the District of Columbia.
With an intradermal vaccination, "basically, you're staying in the skin; you're not going through the skin," said Dr. Daniel Griffin, an infectious disease specialist at Columbia University.
Using a smaller dose with intradermal injection has been done with vaccines for flu and rabies, epidemiologist Dr. Jay Varma in an email.
CNN
The Biden administration is preparing to move forward with a plan to stretch the limited supply of monkeypox vaccine doses that would allow providers to use one-fifth as much per shot, two people familiar with the plans said.
"The skin has special cells that are very good at helping a vaccine stimulate the body's immune system," he wrote.
These cells, called dendritic cells, are better able to produce an immune response, Griffin said.
"They live in the skin, and they're better at teaching the immune system what they need to respond to," he said.
"If you're able to give the monkeypox vaccine intradermally, you can give a smaller dose. ... They just would need to have some sort of demonstration that you get the same immune response," he said.
